FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an expression vector based on a recombinant adenoassociated virus, the use of an expression vector for the prevention of diseases caused by influenza A virus and SARS-CoV-2 virus, and an immunobiological agent for the prevention of diseases caused by influenza A virus and SARS-CoV-2 virus containing an expression vector. In one embodiment, the expression vector carries the recombinant antibody gene, which is single-domain antibodies tetramerized with glycine-serine linkers fused with the Fc fragment of human IgG1.
EFFECT: invention expands the arsenal of means for the prevention of diseases caused by the influenza A virus and the SARS-CoV-2 virus.
13 cl, 9 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) | 2022 |
|
RU2777404C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| ISOLATED MODIFIED CAPSID PROTEIN VPI OF ADENO-ASSOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2820088C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS WITH PROTECTIVE PROPERTIES AGAINST INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2768044C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
